Жулев Н.М., Скоромец А.А., Трофимова Т.Н., Тотолян Н.А. Современная диагностика рассеянного склероза. СПБ, изд-во СПбМАПО 1998, 28 с.

27. Завалишин И.А, Яхно Н.Н., Жученко Т.Д., Ниязбекова А.С. Бетаферон – первый опыт использования для лечения рассеянного склероза в России. Ж.неврологии и психиатрии 1997, 12: 24-27.

28. Завалишин И.А., Кузнецов В.П. с соавт. Цитокины при рассеянном склерозе.//В сб. «Нейроиммунология. Нейроинфекции. Нейроимидж.» (Материалы 4-й научной конференции в СПб) – 1995. – С. 37-38.

29. Завалишин И.А., Сахарова М.Н. с соавт. Взаимоотношения нервной и иммунной систем в патогенезе рассеянного склероза. В: «Нейроиммунология. Нейроинфекции. Нейроимидж.» (Материалы 4-й научной конференции в СПб) 1995: 35-37.

30. Земсков В.М., Земсков А.М. Принципы дифференцированной иммунокоррекции. Иммунология 1996, 3: 4-7.

31. Змушко Е.И., Белозеров Е.С., Митин Ю.А. Клиническая иммунология. С-Пб, «Питер» 2001, 574 с.

32. Ильвес А.Г., Столяров И.Д. Предварительное пилотное испытание препарата " Стресском" у больных рассеянным склерозом. В: «Неврология-Иммунология», ООО «ЛПМ-КОНТАКТ» С-Пб 2001: 102-103.

33. Кетлинский С.А., Калинина Н.М. Иммунология для врача. СПб, «Гиппократ» 1998 156 с.

34. Кирпичникова Г.И., Неверов В.А., Ремезов А.П. Иммунитет, иммунодефициты, иммуноориентированная терапия. СПб 1999, 44 с.

35. Корнева Е.А. Иммунофизиология. СПб, «Наука» 1993.

36. Корнева Е.А., Григорьев В.А., Клименко В.М., Столяров И.Д. Электрофизиологические феномены головного мозга при иммунных реакциях. Ленинград, «Наука» 1990.

37. Кресюн В.И., Бажора Ю.И., Рыбалова С.С. Клинические аспекты иммунофармакологии. Одесса 1993, 208 с.

38. Крыжановский Г.Н., Магаева С.В., Макаров С.В. Нейроиммунопатология. Москва 1997.

39. Кулаков В.В., Демина Т.Л., Бойко А.Н.с соавт. Изучение функциональной активности хелперных клеток при рассеянном склерозе. Иммунология 1993, 3: 41-44.

40. Лебедев В.В., Шелепова Т.М. Иммунофан - регуляторный пептид в терапии инфекционных и неинфекционных болезней. Москва, «Праминко» 1998.

41. Лесков В.П., Чередеев А.Н., Горлина Н.К., Новоженов В.Г. Клиническая иммунология для врачей. Москва, “Фармарус принт” 1997, 124 с.

42. Мазуров В.И., Лил А.М., Стернин Ю.И. Системная энзимотерапия. СПб, «Mucos Pharma» 1995.

43. Майда Е. Справочник по рассеянному склерозу для больных и их близких. Москва, АО «Интерэксперт» 1999.

44. Марков Д.А., Леонович А.Л. Рассеянный склероз. Москва, «Медицина» 1976.

45. Матвеева Т.В., Ибатуллин М.М., Ануфриев А.Ю., Чувашаев И.Р. МРТ-картина у больных с разными типами течения рассеянного склероза. В: Материалы 9-й научно-практической конференции «Нейроиммунология». С-Пб 2000: 78-79.

46. Машковский М.Д. Лекарственные средства. Вильнюс 1993.

47. Никифорук Н.М. Магнитно-резонансная томография в диагностике очаговых изменений головного мозга при рассеянном склерозе. Автореф. дисс. канд. мед. наук. Москва 1998: 16.

48. Новик А.А., Одинак М.М., Мельниченко В.Я. c соавт. Трансплантация стволовых кроветворных клеток периферической крови при рассеянном склерозе. В: «Неврология – Иммунология» (Материалы 10-й Всероссийской конференции «Нейроиммунология») Санкт-Петербург, ООО «ЛПМ-КОНТАКТ» 2001: 201-202.

49. Оганезов В.К., Бойко А.Н., Демина Т.Л. с соавт. Продукция интерлейкина-1 и интерлейкина-6 при рассеянном склерозе. Иммунология 1992, 4: 58-61.

50. Оганезов В.К., Бойко А.Н., Иванов А.Е. с соавт. Цитокиновый статус больных рассеянным склерозом. В: «Клиническая нейроиммунология на пороге XXI века». СПб 1992: 56-60.

51. Петров Р.В., Хаитов Р.М., Пинегин Б.В. Оценка иммунного статуса человека в норме и при патологии. Иммунология 1994, 6: 10.

52. Полежаев Л.В., Александрова М.А. Трансплантация ткани мозга в норме и патологии. Москва, «Наука» 1986: 6-21.

53. Попов В.С. О клинике и эпидемиологии рассеянного склероза. Ж. неврологии и психиатрии 1983, 3: 1330-1334.

54. Речаник Д.П., Матвеева Т.В., Менделевич В.Д. Соотношения клинических характеристик, данных нейровизуализации и эмоциональных особенностей больных с различными вариантами рассеянного склероза. В: «Нейроиммунология – неврология» (материалы 10-й научно-практической конференции «Нейроиммунология») С-Пб, 2001: 236-238.

55. Рятсеп В.И., Куртенков О.А. с соавт. Противоопухолевый иммунитет у человека по данным теста торможения прилипания лейкоцитов. Вопросы онкологии 1980, 26 (8): 3-8.

56. Справочник лекарственных средств Pharmindex. Изд-во Med.Media, 1997.

57. Столяров И.Д. Взаимодействие нервной и иммунной систем при органических поражениях структур головного мозга (экспериментально-клиническое исследование). Дисс. д.м.н. СПб 1996.

58. Столяров И.Д. Огурцов Р.П., Петров А.М. с соавт. Инструментальные и нейроиммунологические характеристики демиелинизирующего процесса при рассеянном склерозе. В: Материалы конференции ВМА 2000: 382.

59. Столяров И.Д., Каримова Р.Р., Ивашкова Е.В. и др. Нейроиммунные аспекты патогенетических взаимодействий при рассеянном склерозе. В: «Фундаментальные науки и прогресс клинической медицины» (материалы конф.). Москва 1998: 201.

60. Столяров И.Д., Николаева Н.В., Ивашкова Е.В. с соавт. Продукция интерлейкинов 1-бета, 6 и фактора некроза опухолей-альфа при рассеянном склерозе. В: Материалы IX конференции «Нейроиммунология». СПб, 2000: 85-86.

61. Столяров И.Д., Огурцов Р.П., Рудас М.С. с соавт. Характеристики демиелинизирующего процесса у пациентов с рассеянным склерозом. Физиология человека 1999, 25 (5): 49-52.

62. Тотолян Н.А. Рассеянный склероз и рассеянный энцефаломиелит. СПб 1998.

63. Тотолян Н.А. Рассеянный склероз: диагностика и лечение с позиции доказательной медицины. Мир медицины 2000, 5-6: 34-37.

64. Тотолян Н.А. Реабилитация при рассеянном склерозе. Мир Медицины 1999, 11-12: 26-27.

65. Тотолян Н.А., Грязева И.В., Климович В.Б., Тотолян А.А. Интратекальный синтез свободных легких цепей иммуноглобулинов и его связь с другими иммунными нарушениями у больных РС. Иммунология 1994, 1: 54-58.

66. Тотолян Н.А., Лугакова О.В. Антитела к галактоцереброзидам мозга в сыворотке и ЦСЖ больных рассеянным склерозом. Журнал неврологии и психиатрии им. Корсакова 1996, 4: 75-77.

67. Тотолян Н.А., Скоромец А.А., Барбас И.М. с соавт. Актуальные практические вопросы диагностики рассеянного склероза. Ученые записки, С-Пб гос. университет им. акад. И.П.Павлова 2000, 7 (3): 37-48.

68. Тотолян Н.А., Скоромец А.А., Трофимова Т.Н., Сорокина М.Н. Особенности диагностики рассеянного склероза в детском возрасте. В: Материалы 10-й научно-практической конференции «Нейроиммунология». С-Пб 2001: 263-266.

69. Тринитатский Ю.В. Магнитно-резонансная томография с контрастным усилением как показатель активности демиелинизирующего процесса при рассеянном склерозе. В: Материалы 10-й научно-практической конференции «Нейроиммунология» С-Пб 2001: 268-270.

70. Трофимова Т.Н. Автореф. на соиск. уч. степ. д.м.н. СПб 1998.

71. Фрейдлин И.С. Иммунная система и ее дефекты. СПб, НТФФ “Полисан” 1998, 111 с.

72. Фюльграфф Г., Пальм Д. Фармакотерапия, клиническая фармакология. Минск, «Беларусь» 1996.

73. Хаитов Р.М., Пинегин Б.В. Основные представления об иммунотропных лекарственных средствах. Иммунология 1996, 6: 4-10.

74. Хайдаров Б.Т., Ниязбекова А.С., Кулов Б.Б. Генетическая детерминированность при рассеянном склерозе и ретробульбарном неврите (иммуногенетическое и биохимическое исследование). В: Материалы VII Всероссийского съезда неврологов. Нижний Новгород 1995: 149.

75. Хондкариан О.А., Завалишин И.А., Невская О.М. Рассеянный склероз. Москва 1987.

76. Хохлов А.П., Савченко Ю.Н. Миелинопатии и демиелинизирующие заболевания. Москва, «Медицина» 1990.

77. Черниговская Н.В., Матвеева Т.С., Огурцов Р.П. с соавт. Клинико-иммунологические параллели в оценке лечения рассеянного склероза. Невропатология 1990, 2: 24-28.

78. Ширинский В.С., Жук Е.А. Проблемы иммуностимулирующей терапии. Иммунология 1991, 3: 7-10.

79. Analysis Group. Interferon beta-1b in the treatment of MS: final outcome of the IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI randomized controlled trial. Neurology 1995; 45: 1277-1285.

80. Arnason B.et al. Neutralizing antibodies: are they an issue? International MS Journal 1997; 4 (2): 40-42.

81. Arnold DL, Riess GT, Matthews PM et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression of multiple sclerosis.Ann neurol 1994; 36: 76-82.

82. Arnold DL, Wolinky IS, Matthews PM, Falini A. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis J Neurol Neurosurg Psychiatry 1998; 64 (1): S94-101.

83. Bakshi R,.Miletich RS, Kinkel PR et al. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. Journal of Neuroimaging 1998; 8: 4.

84. Barkhof F, Fillipi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain, 1997; 120(11): 2059-69.

85. Barkhof F, van Waesberghe JH, Filippi M et al. The European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001; 124(7): 1396-402.

86. Barkhof F. Diagnosis and prognosis in MS by magnetic resonance imaging. Multiple sclerosis 2000; 6 (1): S6.

87. Beck J, Rondot P, Catinot L et al. Increased production of interferon-gamma and tumor necrosis factor precedes clinical manifestation in MS. Acta Neurol Scand. 1988; 78: 318-323.

88. Bertolene K, Coyle PK, Krupp LB et al. Fatigue in multiple sclerosis. Arch. Neurol. 1993; 45: 435-437.

89. Billiau A. Interferons in multiple sclerosis. Neurology 1995; 45 (6): 50-53.

90. Bisaga GN, Posdnyakov AV, Golovkin VI et al. New possibilities of magnetic resonance imaging in diagnosis of multiple sclerosis. The proceeding of V Scientific Conference by Russian National Society of Multiple Sclerosis (RSMS), St. Petersburg, May 26-29, 1996: 16-21.

91. Blinkeenberg M, Jensen CV, Holm S et al. A longitudinal study of cerebral glucose metabolism, MRI and disability in patients with MS. Neurology 1999; 53(1): 149-153.

92. Blinkeenberg M, Rune K, Jensen CV et al. Cerebral glucose metabolism in MS patients with cognitive dysfunction. J Cerebr. Blood Flow. Metab. 1995; 15 (1): S 819.

93. Blinkenberg M,.Rune K, Jonsson A et al. Cerebral metabolism in a case of MS with acute mental disorder. Acta Neurol Scand. 1996; 94: 310-313.

94. BMT-MS Study Group. Comi G, Kappos L, Clanet M et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol 2000; 247(5): 376-82.

95. Books DJ, Leenders KL, Head G et al. Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J. Neurol Neurosurg Psychiatry 1994; 47: 1182-1191.

96. Brainin M, Reisner T, Neuhold A et al. Topological characteristics of brainstem lesions in clinically definite and clinically probable cases of multiple sclerosis: an MRI-study. Neuroradiology 1987; 29(6): 530-4.

97. Brex PA, O(Roirdan JI, Miszkiel KA et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999; 53(6): 1184-90.

98. Bright JJ, Sriram S.TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes. J Immunol 2000 Mar 15; 164(6): 3207-13

99. Brooks DJ, Leenders KL, Head G et al. Studies on regional cerebral oxygen utilization and cognitive function in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1984; 47: 1182-1191.

100. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokines localization in multiple sclerosis lesions: Correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995; 45 (6): S16-S21.

101. Bruck W, Schmied M, Suchanek G et al. Oligodendrocytes in the early course of multiple sclerosis. Ann. Neurol. 1994; 35: 65-73.

102. Burt RK, Traynor AE, Cohen B et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998; 21(6): 537-41.

103. Calabresi PA, Fields NS, Maloni HW, Hanham A, Carlino J, Moore J, Levin MC, Dhib-Jalbut S, Tranquill LR, Austin H, McFarland HF, Racke MK Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 1998 Jul; 51(1): 289-92

104. Camp SJ, Stevenson VL, Thompson AJ et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 1999; 122 (7): 1341-8.

105. Canella B, Raine CS The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995; 37: 424-435.

106. Caroleo MC, Doria G, Pioli C et al. Pineal regulation of immune response and cytokines actions on the CNS. In: Nitric Oxide: Brain and Immune System. (Moncada S, Nistico G, Higgs EA, eds.). London, Portland Press 1993: 19-32.

107. Castelijns JA, Barkhof F Magnetic resonance (MR) imaging as a marker for multiple sclerosis. Biomed Pharmacother 1999; 53 (8): 351-7.

108. Chabot S, Yong VW Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS. Neurology 2000; 55(10): 1497-1505.

109. Chofflon M., Juillard C, Juillard P et al. Tumor necrosis factor-alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992; 3: 523-531.

110. Comi G, Filippi M, Wolinsky JS. European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49(3): 290-7.

111. Comi G, Martinelli V, Filippi M. Interferon beta treatment in multiple sclerosis: the European clinical trials. Multiple Sclerosis 1996; 1: 317-320.

112. Cook SD, Devereux C, Troiano R et al. Combination total lymphoid irradiation and low-dose corticosteroid therapy for progressive multiple sclerosis. Acta Neurol Scand 1995; 91: 22-27.

113. Croxford JL, Triantaphyllopoulos K, Podhajcer OL et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998; 160(10): 5181-7.

114. Davie CA, Barker GJ, Webb SL et al. Persistent functinal deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axonal loss. Brain 1995; 118: 1583-1592.

115. Davie CA, Hawkins CP, Barker GJ et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesion. Brain 1994; 177: 49-58.

116. Dhib-Jalbut S, McFarlin DE. Immunology of multiple sclerosis. Ann. Allergy 1990; 64: 433-444.

117. Drescher KM, Murray PD, Lin X, Carlino JA, Rodriguez M. TGF-beta 2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis J Immunol 1998 Aug 15; 161(4): 1772-7

118. Durelli L, Ferrero B, Oggero A et al. and the INCOMIN Trial Study Group. A multicenter trial clinical and MRI efficacy of interferon beta-1a and beta-1b in multiple sclerosis. J of Neurology 2001; 248 (2): 63.

119. European Study Group on Interferon-beta 1b in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of Interferon-beta 1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.

120. Fassas A, Anagnostopoulos A, Kazis A et al. Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy. J Clin Immunol 2000; 20(1): 24-30.

121. Fazekas F, Offenbacher H, Fuchs S et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 38 (12): 1822-5.

122. Ferribi D, De Seze J, Stojkovic T et al. Cerebral and brainstem atrophy: correlation with disability in multiple sclerosis. Multiple sclerosis 2001; 7 (1): S42, P-097.

123. Filippi M, Rovaris M, Rocca MA et al. European/Canadian Glatiramer Acetate Study Group Glatiramer acetate reduces the proportion of new MS lesions envolving into “black holes”. Neurology 2001; 57(4): 731-3.

124. Fox NC, Jenking C, Leary SM et al. Progressive cerebral atrophy in multiple sclerosis: a serial study using registered, volumetric MRI. Neurology 2000; 54 (4): 807-12.

125. Francis DA. Glatiramer acetate (Copaxone). Int J Clin Pract 2001; 55(6): 394-8.

126. Francis G, Evans A, Panitch H. MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis. Ann Neurol 1997, 42: 467-477.

127. Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. Brain 1991; 114: 557-572.

128. Goodkin DE, Bailly RC, Teetzen M et al. The efficacy of azathioprin in relapsing-remitting multiple sclerosis. Neurology 1991; 41: 20-25.

129. Goodkin DE, Rudick RA, Daughtry MM et al. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996; 47: 1153-1157.

130. Goodkin DE, Rudick RA, Schwetz KM et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995; 37: 30-40.

131. Gran B, Tranquill LR, Chen M et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 55(11): 1704-14.

132. Grossman RI, Gonzalez-Scarano F, Atlas SW et al. Multiple sclerosis: gadolinium enchansement in MRI imaging. Radiology 1986; 161: 721-725.

133. Grossman RI, Lenkinski RE, Ramer KN et al. MR proton spectroscopy in multiple sclerosis. AJNR 1992; 13: 1535-1543.

134. Haas J High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 2000; 6 (2): S18-20; discussion S33.

135. Hartlung H.P. Immunomediated demyelination. Ann.Neurol. 1993; 33: 563-567.

136. Hartung HR, Gonsette RE The MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind European phase III multicentre study. Clinical data. Multiple Sclerosis 1998; 4: 325.

137. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. (Invited review). Brain 1997; 120: 865-916.

138. Howard L. Oral tolerance with Copolymer 1 for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A. 1999; 96(7): 3333-5.

139. Huk W.I., Gademann G, Fridemann G. Magnetic resonance imaging of central nervous system diseases. In: Functional anatomy imaging neurological symptoms pathology. Berlin, Springer Verl. 1990: 450.

140. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.

141. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.

142. Ishikawa M, Jin Y, Guo H et al. Nasal administration of transforming growth factor-beta1 induces dendritic cells and inhibits protracted-relapsing experimental allergic encephalomyelitis. Mult Scler 1999; 5(3): 184-91.

143. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann.Neurol 1996; 39: 285-294.

144. Jain KK. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Investig Drugs 2000; 5: 1139-49.

145. Jin YX, Xu LY, Guo H, Ishikawa M, Link H, Xiao BG TGF-beta1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells. J Autoimmun 2000 May; 14(3): 213-20

146. Johnson KP, Brooks BR, Cohen JA et al. Copolimer-1 redues relapse rate and improved disability in relapsing-remitting multiple sclerosis. Results for a phase III multicenter, double blind, placebo controlled trial. Neurology 1995; 45: 1268-1276.

147. Johnson KP, Brooks BR, Ford CC et al. Copolymer 1 Multiple Sclerosis Study Group. Substained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6(4): 255-66.

148. Kappos L. et al. Interferon beta in the treatment of MS – closing remarks. Multiple Sclerosis 1995; 1: S64-S66.

149. Karussis D, Vourka-Karussis U, Mizrachi-Koll R, Abramsky O. Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler 1999; 5(1): 17-21.

150. Kermode AG, Tofts PS, Thompson AJ et al. Heterogenety of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40: 229-235.

151. Kesselring J et al. Acute disseminated encephalomyelitis: MRI findings and the distinction from multiple sclerosis. Brain 1990; 113: 291.

152. Kesselring J, Lassmann H. Pathogenesis /Multiple sclerosis/. J. Kesselring, ed., Cambridge University Press, 1997: 54-62.

153. Kesselring J. Multiple Sclerosis. – USA: Cambridge University Press, 1997.

154. Khan OA, Tselis AC, Kamholz J et al. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 2001; 8(2): 141-8.

155. Korneva E.A., Grigoriev V.A., Stoliarov I.D. Brain reaction to antigen. J. Neurosci. Res. 1988; 19(2): 134-136.

156. Kozak T, Havrdova E, Pit'ha J et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000; 25(5): 525-31.

157. Kracke A, von Wussow P, Al-Masri AN et al. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000; 54(1): 193-9.

158. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(12): 1444-1452.

159. Kutrzke JF. MS epidemiology world wide. One view of current status. Acta Neurol Scand.1995; 91(161): 23-33.

160. Lauer K. Environmental associations with the risk of multiple sclerosis: the contribution of ecological studies. Acta Neurol Scand. 1995; 91(161): 77-88.

161. Li DK, ZhaoG, Paty DW. T2 hyperintensities: findings and significans. Neuroimaging Clin N Am 2000; 10(4): 717-38.

162. Link J, Soderstrom M, Olsson T et al. Increased TGF-(, IL-4 and IFN-(in MS. Ann Neurol 1994; 35: 197-203.

163. Liu C, Blumhardt LD. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. J Neurol Sci 2000; 181(1-2): 33-37.

164. Liu MT, Keirstead HS, Lane TE.). Neutralization of the chemokine cxcl10 reduces inflammatory cell invasionand demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol 2001 Oct 1; 167(7): 4091-7

165. Losseff NA, Wang L, Lai HM et al. Progreessive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996; 119: 2009-2019.

166. Maestroni GJM, Pierpaoli W. Melatonin: a principal neiroimmunomodulatory and antistress hormone. Immunol. Lett 1987; 16: 355-362.

167. Mancardi GL, Sardanelli F, Parodi RC et al. Effect of copolimer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998; 50: 1127-1133.

168. Mancardi GL, Sardanelli F, Parodi RC et. al. Effect of copolimer-1 on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis. Neurology 1998, 50: 1127-1133.

169. Mandalfino P, Rice G, Smith A et al. Bone marrow transplantation in multiple sclerosis. J Neurol 2000; 247(9): 691-5.

170. Masek K, Petrovicky P. Regulatory systems in the brain for the immune response. Nitric Oxide: Brain and Immune System. Moncada S, Nistico G, Higgs EA, eds., Portland Press, London, 1993: 13-18.

171. McDonald W, Compston A, Edan G et al. Recommended Diagnostic Criteria for Multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology 2001; 50 (1): 121-127.

172. Metter EJ, Riege WH, Kuhl DE, Phelps ME. Cerebral metabolic relationships for selected brain regions in healthy adults. J. of Cerebral Blood Flow and Metabolism 1984; 4 (1): 1-7.

173. Miller D, Khah O, Sheremata W, Blumhardt L, Rice G, O’Connor P, the International Antegren MS Trial Group. Results of a double-blind, placebo-contolled, phase II trial of Antegren TM (Natalizumab) in subjects with relapsing multiple sclerosis. Multiple Sclerosis 2001; 7(1): S16.

174. Miller D.H., Barkhof F, Berry I. et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J. Neurol. Neurosurg. Psychiatry 1991; 54: 683-688.

175. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance technigues in understanding and managing multiple sclerosis. Brain 1998; 121: 3-24.

176. Miller DH, Molyneux PD, Barker GJ et al. Effect of interferon-beta 1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta 1b in secondary progressive multiple sclerosis. Ann Neurol 1999; 46(6): 850-9

177. Molyneux PD, Kappos L, Polman C et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000; 123 (11): 2256-63.

178. Munschauer FE 3rd, Kinkel RP, William C. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997; 19(5): 883-93.

179. Newcombe J, Hawkins CP, Henderson CL et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991; 114: 1013-1023.

180. Oentrich W, Dose T, Friedmann D et al. Interferon beta-1b (Betaferon) therapy in patients with relapsing-remitting multiple sclerosis: findings of a prospective, multicenter study of disease progression. Nervenarzt 2001; 72(4): 286-92.

181. Oliveri RL, Valentino P, Russo C et al. Randomized trial comparing two different high doses of methylprednisolone in MS. A clinical and MRI study. Neurology 1998; 50: 1833-1836.

182. Orvieto R, Achiron R, Rotstein Z et al. Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol 1999; 82(2): 91-4.

183. Panitch HS, Hirsch RL, Schindler J et al. Treatment of MS with gamma interferon: exacerbation associated with activation of the immune system. Neurology 1987; 37: 1097- 1120.

184. Patti F, Di Stefano M, De Pascalis D. et al. May the exist specific MRI findings predictive of dementia in MS patients? Funct Neurol. 1995; 10 (2): 83-90.

185. Paty DW, Li D, Zhao GJ. MRI in multiple sclerosis. Implication for diagnosis and treatment. Ares-Serono Int., 1999: 1-36.

186. Paty DW, Oger JJF, Kastrikof LF. MRI in the diagnosis of MS: a prospektive study with comparison of clinical evaluation, evokepotentials, oligoclonal banding and CT. Neurology 1988; 38 (2): 180-184.

187. Paulesu E, Perani D, Fazio F et al. Functional basis of memory impairment in multiple sclerosis: a (18F)FDG PET study. Neuroimage 1996; 4(2): 87-96.

188. Petrov A, Nikolaeva N, Ivashkova E et al. Cytokine profile and neuropsychological battery in multiple sclerosis patients. Variations with disease stage. Revue Neurologique 2000; 156 (3): 3S175-3S176.

189. Porcel J, Barrios M, Borras C et al. Memory in multiple sclerosis: review of perfomance and relationship with clinical variables and neuroimaging. (Article in Spanish.) Rev Neurol. 1998; 27(160): 1034-42.

190. Poser CM et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.

191. Poser CM, Paty D, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann.Neurol 1983; 13(2): 227-231.

192. PRISMS (Preventation of Relapses and Disabability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group Rundomized double-blind, placebo-controlled study of Interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.

193. Richert ND, Zierak MC, Bash CN et al. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler 2000; 6(2): 86-90.

194. Roelcke U, Kappos L, Lechner-Scott J et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48 (6): 1566-71.

195. Romine J, Sipe J, Koziol J et al. A double-blind, placebo-controlled, randomized trial of Cladribine in relapsing-remitting multiple sclerosis. Proc Assos Am Phys 1999; 111: 35-44.

196. Rudick RA, Goodkin DE. Multiple sclerosis Therapeutics. 2-nd ed. London, M.Dunitz 2000: 1-573.

197. Sailer M, Losseff NA, Wang L et al. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A progressive 18 months follow-up study. Eur J. Neurol. 2001; 8(1): 37-42.

198. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2001; 2 (7): 1149-65.

199. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind randomized, placebo-controlled study of oral high-dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529-534.

200. Sipe JC, Romine JS, Koziol JA et al. Cladribine in the treatment of the chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.

201. Siva A., Kesselring J., Thompson A. Frontiers in Multiple Sclerosis. UK: London, 1999.

202. Sorensen PS The effect on MRI of gammaglobulin treatment in relapsing multiple sclerosis. Mult Scler 2000, 6 (2): S14-7.

203. Stangel M, Boegner F, Klatt CH et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68(1): 89-92.

204. Stawiarz L, Helms G, Link H/ Changes in tissue water content in MS lesion at different stages of their evolution evaluated by proton MRS. Multiple sclerosis 1997; 3: 295.

205. Stoliarov I, Petrov A. Ogurtsov R. et al. Immunological monitoring in patients with multiple sclerosis can help to prevent exacerbation. Multiple Sclerosis 1998; 4 (4): 336.

206. Stoliarov I, Roudas M, Ilves A et al. Neuropsychological battery and PET in multiple sclerosis patients. Multiple Sclerosis 1999; 5 (1): S 36.

207. Stoliarov ID, Petrov AM, Ogurtsov RP et al. The immunological peculiarities in patients with multiple sclerosis. J. Neuroimmunology 1995; 1: 71.

208. Strasser-Fuchs S, Fazekas F, Deisenhammer F et al. The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Mult Scler 2000; 6 (2): S9-13.

209. Sun X, Tanaka M, Kondo S et al. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med 1998; 12(2): 89-94.

210. Teitelbaum D, Arnon R, Sela M. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci U S A 1999; 96(7): 3842-7.

211. Teksam M, Tali T, Kocer B, Isik S. Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 2000, 42(12): 885-9.

212. The Multiple Sclerosis Study Group. Efficacy and toxity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591-605.

213. Thompson A, Kennard C, Swash M. et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapses in MS. Neurology 1989; 39: 969-971.

214. Tsukada N, Matsuda M et al. In vitro intercellular adhesion moleculae-1 expression on brain endothelial cells in multiple sclerosis. J.Neuroimmunol 1994; 49: 181-187.

215. van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol 2000; 20(1): 10-6.

216. van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, Schrijver HM et al. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann Neurol 2000; 48(3): 313-22.

217. van Buchem MA, Tofts PS. Magnetization transfer imaging. Neuroimaging Clin N Am 2000; 10(4): 771-88.

218. Vandenbark AA, Morgan E, Bartholomew R et al. TCR peptide therapy in human autoimmune diseases. Neurochem Res 2001; 26(6): 713-30.

219. Villoslada P, Hauser SL, Bartke I et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 2000; 191(10): 1799-806.

220. Wallace CJ, Seland TP, Fong TC. Multiple sclerosis: the impact of MRI imaging. AJR 1992; 158: 849-857.

221. Wang X, Chen M, Wandinger KP et al. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 2000; 165(1): 548-57.

222. Weber F, Polak T, Gunther A et al. Synergistic immunomodulatory effects of interferon-beta 1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998; 44(1): 27-34.

223. Weiner HL, Mackin GA, Orav EG et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-918.

224. Wilson M, Morgan PS, Lin X et al. Quantitative diffusion weighted magnetic resonance imaging, cerebral atrophy, and disability in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2001; 70(3): 318-22.

225. Wolinsky J.S. Multiple sclerosis. Curr. Neurol. 1993; 13: 167.

226. Xu LY, Ishikawa M, Huang YM, Levi M, van der Meide PH, Wahren B, Link H, Xiao BG. The complexicity of cytokine treatment in ongoing EAE induced with MBP peptide 68-86 in Lewis rats. Clin Immunol 2000 Apr; 95(1 Pt 1): 70-8